← Back to Search

Other

BTRX-335140 for Depression

Phase 2
Waitlist Available
Research Sponsored by BlackThorn Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Summary

This trial is testing a new drug relative to placebo to see if it improves symptoms of major depressive disorder, specifically anhedonia and anxiety, in adults. The trial will last 8 weeks and use the HAMD-17 Scale to assess the results.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hamilton Depression Rating Scale (HAMD-17)
Secondary outcome measures
Assessment of safety through the occurrence of TEAEs, SAEs, and adverse events of special interest (AESIs)
Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) score
Anxiety
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BTRX-335140Experimental Treatment1 Intervention
BTRX-335140
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BTRX-335140
2019
Completed Phase 2
~210

Find a Location

Who is running the clinical trial?

Neumora Therapeutics, Inc.Industry Sponsor
5 Previous Clinical Trials
1,706 Total Patients Enrolled
4 Trials studying Depression
1,374 Patients Enrolled for Depression
BlackThorn Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
430 Total Patients Enrolled
4 Trials studying Depression
318 Patients Enrolled for Depression
Jane Tiller, MBChBStudy DirectorBlackThorn Therapeutics, Inc., a wholly owned subsidiary of Neumora Therapeutics, Inc.
~35 spots leftby Sep 2025